Melissa Mudd
Family · Saint Louis, MONPI 1407336472
Payments from drug & device makers
Across 174 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$424
- Novo Nordisk$402
- AstraZeneca$269
- Takeda Pharmaceuticals U.S.A., Inc.$219
- Boehringer Ingelheim$213
- Lilly USA, LLC$165
- plus $991 from 21 others
What the payments were for
- Food & beverage$2,683100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 25 | $424 |
| Novo Nordisk | 28 | $402 |
| AstraZeneca | 16 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $219 |
| Boehringer Ingelheim | 13 | $213 |
| Lilly USA, LLC | 10 | $165 |
| AbbVie | 12 | $146 |
| GSK | 10 | $126 |
| Biohaven Pharmaceuticals, Inc. | 6 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $87 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| Gilead | 3 | $47 |
| Merck | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $41 |
| Dexcom, Inc. | 3 | $41 |
| Johnson & Johnson | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
| Edwards Lifesciences | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Bayer | 1 | $14 |
| Amgen | 1 | $13 |
How this compares
$2,683 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $9,124 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,816 |
| Atorvastatin Calcium | 96 | $804 |
| Gabapentin | 23 | $609 |
| Fluticasone Propionate | 37 | $580 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $560 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 15 | $450 |
| Buspirone Hcl | 12 | $434 |
| Rosuvastatin Calcium | 46 | $433 |
| Metoprolol Succinate | 36 | $428 |
| Losartan Potassium | 45 | $427 |
| Valsartan | 11 | $409 |
| Amlodipine Besylate | 89 | $370 |
| Omeprazole | 38 | $331 |
| Fluoxetine Hcl | 15 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $269 | $9,12411 claims |
| GSKBreo Ellipta | $126 | $4,81612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.
Other family in Saint Louis
- Rebecca SeabaughSaint Louis$68K
- Jordan PerezSaint Louis$43K
- Lindsay GwaltneySaint Louis$28K
- Sara WoottenSaint Louis$21K
- Kelly RobertsSaint Louis$17K
- Matthew CarySaint Louis$15K
- Philip DudakSaint Louis$14K
- Kenan SahbazSaint Louis$14K
- Nicole CarrSaint Louis$14K
- Ashley GarrettSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.